MK-2206 is under clinical development by Merck & Co and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect MK-2206’s likelihood of approval (LoA) and phase transition for Non-Small Cell Lung Cancer took place on 18 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MK-2206 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
MK-2206 overview
MK-2206 is under development for the treatment of prostate cancer, non-small cell lung cancer, metastatic breast cancer, small cell lung cancer, thymic malignancies and small lymphocytic lymphoma (SLL) and melanoma. The drug candidate is administered by orally. MK-2206 is a selective non-ATP competitive allosteric Akt inhibitor.
It was also under development for endometrial cancer, recurrent platinum-resistant ovarian, fallopian tube, peritoneal cancer, colorectal carcinoma, malignant glioma, HER-2 positive breast cancer, metastatic neuroendocrine tumors, head and neck cancer, metastatic pancreatic cancer, metastatic nasopharyngeal carcinoma, hepatocellular carcinoma, relapsed or refractory acute myeloid leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, relapsed or refractory diffuse large B-cell lymphoma, refractory biliary cancer, gastric cancer, gastroesophageal junction cancer, chronic lymphocytic leukemia (CLL), bile duct cancer (Cholangiocarcinoma), metastatic adenoid cyst carcinoma and gallbladder cancer.
Merck & Co overview
Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
Quick View MK-2206 LOA Data
| Report Segments |
|
| Drug Name |
|
| Administration Pathway |
|
| Therapeutic Areas |
|
| Key Developers |
|
| Highest Development Stage |
|
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
